How Changing Your Diet Could Have a Major Impact on Managing Lupus Symptoms
After Jewell Singletary was diagnosed with lupus, she developed rheumatoid arthritis as well—a common pairing, since both are autoimmune conditions—and had to use a cane to navigate her college campus. When she graduated, the now 38-year-old New Jersey resident decided to be more focused on supporting her health, in an effort to maintain her mobility as she began her career. She started in the kitchen. First to be tossed were sugary drinks, fried foods, and highly processed options, she says. Once she eliminated them, it didn’t take long before she could discard one more important item: her cane. [time-br...
Source: TIME: Health - June 29, 2022 Category: Consumer Health News Authors: Elizabeth Millard Tags: Uncategorized Diet & Nutrition freelance healthscienceclimate Source Type: news

What are Potential Problems with Placental Abnormalities?
Discussion “The placenta is a unique organ that sits at the interface of, and facilitates nearly all interactions between, maternal and fetal physiology. It is the sole source of oxygen and nutrition for the fetus, and provides a protective barrier against external insults. The placenta is also a highly adaptable organ that is capable of showing a wide range of pathological changes in response to various maternal and fetal factors and stressors.” The placenta has 3 layers: the amnion (fetal side), the chorion, and decidua (maternal side). In addition to making observations about the maternal and fetal sides, co...
Source: PediatricEducation.org - June 27, 2022 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

Chilblains: An Old But Now More Common Problem
Discussion Chilblains is also known as perniosis is an “…inflammatory dermatosis that generally affects the dorsal feet or hands during the periods of damp and cold, but not freezing, conditions…” It produces acryl lesions. Chilblains may be derived from the Old English words “chill” and “blegen” (sore). Pernio is thought be derivative of pern(a) or haunch of the leg as the feet and legs are commonly affected. Chilblain is usually idiopathic but has been associated with Raynaud disease, blood problems including cryofibrinogenemia and rheumatologic conditions such as systemic ...
Source: PediatricEducation.org - May 30, 2022 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

New Data From Two Large Studies Reinforce Effectiveness of Dual Pathway Inhibition (DPI) with XARELTO ® (rivaroxaban) Plus Aspirin in Patients with Coronary Artery Disease (CAD) and/or Peripheral Artery Disease (PAD)
RARITAN, N.J., May 23, 2022 – Findings from the XARELTO® (rivaroxaban) Phase 3 COMPASS Long-Term Open Label Extension (LTOLE) study and the XARELTO® in Combination with Acetylsalicylic Acid (XATOA) registry have been published in the European Society of Cardiology’s (ESC) European Heart Journal, Cardiovascular Pharmacotherapy. Additionally, the XATOA registry was presented at the American Congress of Cardiology’s 71st Annual Scientific Session (ACC.22). These studies provide further evidence supporting the role of dual pathway inhibition (DPI) with the XARELTO® vascular dose (2.5 mg twice daily plus aspirin 100 mg...
Source: Johnson and Johnson - May 23, 2022 Category: Pharmaceuticals Source Type: news

Novel Antibody Response Test May Aid in Lyme Disease Diagnostics, Detect Recurrence Novel Antibody Response Test May Aid in Lyme Disease Diagnostics, Detect Recurrence
A test that detects antiphospholipid antibodies in the blood of Lyme disease patients shows potential for identifying the disease sooner than current methods and possibly tracking response to therapy and recurrence, researchers say.Reuters Health Information (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - April 5, 2022 Category: Pathology Tags: Infectious Diseases News Source Type: news

Data from New VOYAGER PAD Analyses at ACC.22 Reinforce Benefit of XARELTO ® (rivaroxaban) Plus Aspirin in Patients with Peripheral Artery Disease (PAD) and Various Co-Morbid Conditions
RARITAN, N.J., April 1, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from new analyses from the Phase 3 VOYAGER PAD clinical trial reinforcing the benefit of the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) in reducing severe vascular events in patients with PAD after lower-extremity revascularization (LER), a procedure that restores blood flow to the legs. Data from the two analyses demonstrate the role that the XARELTO® vascular dose plays in PAD patients with and without chronic kidney disease (CKD) and in PAD patients with and ...
Source: Johnson and Johnson - April 1, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

Antibody-Activated Endothelial Cells Increase the Risk of Blood Clots with Covid-19
Antiphospholipid antibodies activity may help explain hypercoagulation associated with late stages of Covid-19 and long-haul disease. Blood samples from nearly 250 individuals hospitalized for Covid-19 found that these “rouge” antibodies activate endothelial cells, risking widespread blood clots. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - March 4, 2022 Category: Pharmaceuticals Authors: William A. Haseltine, Contributor Tags: Healthcare /healthcare Innovation /innovation business pharma & Source Type: news

EULAR CVD Management Guidance Focuses on Gout, Lupus, Vasculitis EULAR CVD Management Guidance Focuses on Gout, Lupus, Vasculitis
The recommendations advise on managing cardiovascular health in patients with gout, vasculitis, systemic sclerosis, myositis, Sj ögren syndrome, lupus, antiphospholipid syndrome, and other diseases.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - February 24, 2022 Category: Allergy & Immunology Tags: Rheumatology News Source Type: news

Scientists pinpoint mechanisms associated with severe COVID-19 blood clotting
Researchers found circulating antiphospholipid antibodies, which can be more common among people with autoimmune disorders. (Source: National Institutes of Health (NIH) News Releases)
Source: National Institutes of Health (NIH) News Releases - February 17, 2022 Category: American Health Source Type: news

FDA Approves Two New Indications for XARELTO ® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
RARITAN, NJ, Dec. 20, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved two pediatric indications for XARELTO® (rivaroxaban): the treatment of venous thromboembolism (VTE, or blood clots) and reduction in the risk of recurrent VTE in patients from birth to less than 18 years after at least five days of initial parenteral (injected or intravenous) anticoagulant treatment; and thromboprophylaxis (prevention of blood clots and blood-clot related events) in children aged two years and older with congenital heart disease who have...
Source: Johnson and Johnson - December 21, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen to Present the Strength and Promise of its Hematologic Malignancies Portfolio and Pipeline at ASH 2021
RARITAN, N.J., November 4, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral presentations, plus more than 35 investigator-initiated studies will be featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. ASH is taking place at the Georgia World Congress Center in Atlanta and virtually from December 11-14, 2021.“We are committed to advancing the science and treatment of hematologic malignancies and look forward to presenting the latest research from our robust portfolio and pipeline during ASH...
Source: Johnson and Johnson - November 5, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

New Phase 3 Data Suggest Positive Effect and Show Similar Safety with XARELTO ® (rivaroxaban) Compared to Aspirin in Pediatric Fontan Procedure Patients at Risk for Blood Clots and Blood Clot-Related Events
RARITAN, NJ, September 27, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new data from the Phase 3 UNIVERSE study showing treatment with XARELTO® (rivaroxaban) in an oral suspension formulation, compared to treatment with aspirin, was associated with numerically fewer blood clots and clinical events strongly associated with blood clots in pediatric patients (aged 2-8 years) who have undergone the Fontan procedure. [1] These findings, which were published this month in the Journal of the American Heart Association and included in a recent New Drug Application submitted to the U.S. F...
Source: Johnson and Johnson - September 27, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

FDA Approves Expanded Peripheral Artery Disease (PAD) Indication for XARELTO ® (rivaroxaban) Plus Aspirin to Include Patients After Lower-Extremity Revascularization (LER) Due to Symptomatic PAD
RARITAN, N.J., August 24, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded peripheral artery disease (PAD) indication for the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) to include patients following recent lower-extremity revascularization (LER) due to symptomatic PAD. The approval is based on data from the Phase 3 VOYAGER PAD study. With this approval, XARELTO® is the first and only therapy indicated to help reduce the risks of major cardiovascular (CV) events in p...
Source: Johnson and Johnson - August 24, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

COVID-19 vaccination: blood clotting information for healthcare professionals, PHE ( updated 23rd August 2021)
Information for healthcare professionals on blood clotting following COVID-19 vaccination. 23 August 2021Updated guidance document. 8 June 2021Updated to include: antiphospholipid syndrome, interchangeability of COVID-19 vaccines, samples required for whole genome sequencing and the latest MHRA data. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - August 23, 2021 Category: Consumer Health News Source Type: news

A 28-Year-Old With Antiphospholipid Syndrome A 28-Year-Old With Antiphospholipid Syndrome
This week ' s question involves antiphospholipid syndrome.Osmosis (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 9, 2021 Category: Consumer Health News Tags: Med Students Interactive Quiz Source Type: news